Evaluation of some immune and inflammatory responses in diabetes and HIV co-morbidity

Afr Health Sci. 2023 Mar;23(1):120-128. doi: 10.4314/ahs.v23i1.14.

Abstract

Background: Co-existence of diabetes in the HIV infected reportedly further complicates the attendant impairment of immunity and increases susceptibility to opportunistic infections.

Objective: This study aimed to evaluate some immune and inflammatory parameters in HIV and type 2 diabetes (T2D) co-morbidity: Immunoglobulin M and G (IgM and IgG), Interleukin-6, CD4+ T-cells and C-reactive protein.

Method: The study involved 200 subjects grouped according to their HIV and diabetes status: Group 1 'Diabetic HIV seropositive' (n=40), Group 2 'Non diabetic HIV seropositive'(n=60), Group 3 'Diabetic HIV seronegative'(n=50), and Group 4 'Control non diabetic HIV seronegative'(n=50). Blood samples were collected for testing.

Results: CRP levels were significantly elevated in diabetes and HIV co-morbidity compared to other groups. IL-6 levels were significantly higher in diabetics with or without HIV infection. In addition, IL-6 was significantly elevated in individuals with poor glycemic control (HbA1c > 9.0%) compared to those with good glycemic control. IgG and IgM levels in diabetic HIV seropositive subjects were highest compared with other groups.

Conclusion: The increased IL-6, CRP, IgG, IgM and decreased CD4+ T cell counts observed in co-morbidity suggest that HIV and T2D co-morbidity exacerbate the immune and inflammatory impairment observed in either disease entity.

Keywords: Diabetes; HIV; co-morbidity; glycemic control; immune responses; inflammation.

MeSH terms

  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / epidemiology
  • HIV Infections* / complications
  • HIV Infections* / epidemiology
  • Humans
  • Immunoglobulin G
  • Immunoglobulin M
  • Interleukin-6
  • Morbidity

Substances

  • Interleukin-6
  • Immunoglobulin G
  • Immunoglobulin M